Twelve new 3-(4-substituted benzyl)-5-(4-substituted phenyl)-1-phenyl-4, 5-dihydro-1H-pyrazole derivatives were synthesized by reacting 1-(4-substituted phenyl)-4-(4 substituted phenyl) but-3-en-2-one and phenyl hydrazine in ethanol. 1-(4-substituted phenyl)-4-(4 substituted phenyl) but-3-en-2-one were synthesized by condensation of substituted phenylacetone and substituted benzaldehyde in NaOH solution. The synthesized compounds were confirmed by spectra data. The compounds were evaluated in-vitro for their antibacterial, antifungal, anti-tubercular activity and in-vivo for their anti-inflammatory activity. Compounds P 25 , P 29 , P 31 and P 32 were found to exhibit good antimicrobial and anti-inflammatory activity.
INTRODUCTION
Infections play an important role in more diseases; among them many communicable diseases have been effectively contained. Infectious diseases associated with pain and inflammation remains a major cause of morbidity and mortality; particularly in developing countries. Especially tuberculosis (TB) is the second leading cause of death. However the increasing prevalence of antimicrobial resistance among pathogenic microbes is increasing. It is currently estimated that within the next 10 years many antimicrobial agents currently employed for treatment of infectious
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Billions of dollars are being spent by pharmaceutical companies to identify and develop potent therapeutic agent to over come these challenge. According to a literature survey, in present years a significant portion of research work is been carried out in heterocyclic chemistry. Among them considerable attention has been focused on pyrazoline derivatives, as they posses a variety of significant and diverse pharmacological activities such as antibacterial 4 , antifungal 5 , antiviral 6 , antitubercular 7 , antiamoebic 8 , anti-inflammatory 9 , analgesic 10 , antidepressant 11 , anticancer 12 and antidiabetic activity 13 .
Keeping in view, it was though to design the novel new chemical entities and in continuation of our previous work 14 we report the synthesis of new substituted pyrazoline derivatives and evaluate them for their antibacterial, antifungal, antitubercular and anti-inflammatory activity.
MATERIAL AND METHODS
The chemical and solvents were purchased commercial of analytical grade. Melting points were determined in open tube capillary method and were uncorrected. The homogeneity of the synthesized compounds was routinely checked by thin layer chromatography. IR spectra of all compounds were recorded on a Jasco FTIR-460 spectrometer using KBr disc method.
1 HNMR spectra were recorded on Bruker Avance II 400 NMR spectrometer using DMSO/ CDCl 3 as solvent and TMS as an internal standard.
General procedure for the synthesis of 1-(4-substituted phenyl)-4-(4 substituted phenyl) but-3-en-2-one 4 (C 25, 26, 28, 29, 31, 32, 34, 35 ). 15 An equimolar mixture of 4-substituted phenylacetone and 4-substituted benzaldehyde was added to a rapidly mechanically stirred solution of NaOH (2g in200 ml) at 65 0 C. After 18 hours the mixture was cooled at room temperature and extracted with five 50 ml portion of CH 2 Cl 2 . The extract was washed with water and dried over MgSO 4 and solvent was evaporated under reduced pressure. The crude product obtained was recrystallized from appropriate solvent. A solution of 10% NaOH (8-10ml) was added drop wise to a well stirred equimolar solution of substituted phenylacetone and 4-nitrobenzaldehyde in 20ml of ethanol and was stirred for 24 hours in ice-bath. The reaction was monitored by TLC. Then the mixture was diluted with ice-water and acidified with conc. HCl. The crude product was filtered and recrystallized from appropriate solvent.
General procedure for the synthesis of 3-(4-substituted benzyl)-5-(4-substituted phenyl)-1-phenyl-4, 5-dihydro-1H-pyrazole 6 (P 25 -P 36 ). 16 To a magnetically stirred solution of 1-(4-substituted phenyl)-4-(4 substituted phenyl) but-3-en-2-one (C 25-36 ) in ethanol (30 ml) at room temperature equimolar quantity of phenyl hydrazine was added drop wise. The mixture was stirred continuously till the disappearance of starting material (6-10 hours); the reaction was monitored by TLC. Then the solvent was evaporated under reduced pressure to give a crude mass, which was recrystallized from appropriate solvent. 
4-[5-(4-fluoro-benzyl)-2-phenyl-3,4-dihydro-2H-pyrazol-3-yl]-phenol(P 29 )
Yield-60.69%, m. 
Antimicrobial Activity

17-19
The antibacterial activity of all newly synthesized pyrazoline derivatives was carried out in-vitro by cup plate agar diffusion method, against Staphylococcus aureus, Enterococcus. Faecalis (Gm +ve bacteria), Escherichia coli, Klebsiella. Pneumonia (Gm -ve bacteria) at 75 µg level. Similarly the antifungal activity was carried out against two strains of fungi Aspergillus niger and Candida albicans at 75 µg level. Ciprofloxacin and Fluconazole were used as standard drugs respectively at 75 µg /ml. Dimethyl formamide was Control test which showed no inhibition of the microbial growth. The antibacterial and antifungal activity of synthesized compounds is given in table 1.
Anti-Tubercular Activity 20
The anti-tubercular screening of all synthesized pyrazoline derivatives was carried out by Middle brook 7H9 broth against Mycobacterium tuberculosis of H37Rv strain by Microplate Alamar Blue Assay (MABA) method. This method is nontoxic and shows good correlation with BACTEC radiometric method.
All outer perimeter wells of sterile 96 wells plate were added 200µl of sterile deionzed water to minimized evaporation of medium in the test wells during incubation. 100 µl of the Middlebrook 7H9 broth was added in 96 wells plate and serial dilution of compounds were made directly on plate. The final drug concentrations tested were 0.01 to 20.0 µl/ml. 100 µl of mycobacterium tuberculosis inoculum was added to the 96 wells plate yielding a final volume of 200 µl per well. Plates were covered and sealed with parafilm and incubated at 37ºC for five days. After this, 25µl of freshly prepared 1:1 mixture of Almar Blue reagent and 10% tween 80 was added to the plate and incubated for 24 hrs. A blue color in the well was interpreted as no bacterial growth, and pink color was scored as growth. Isoniazid was used as standard drug. (Table 1 )
Acute oral toxicity
The acute oral toxicity of newly synthesized pyrazoline derivatives was determined by using Swiss albino mice (22-30 g) as per the guidelines set by OECD, revised draft guidelines 423, received from CPCSEA. Animal ethical committee clearance was obtained for carrying out the experiment (IAEC/MMCP/2011-12/06).
Anti-inflammatory Activity 21
All the synthesized compounds were screened for in-vivo anti-inflammatory activity by carrageenan induced rat hind paw method. Rats were assigned into 14 groups of 6 animals each weighing 150-200 g. The first group was administered 0.5% w/v of sodium CMC, which served as control. Group II was administered 100 mg/kg body weight of Diclofenac sodium as standard drug. Group III to XIV received 200 mg/kg body weight of synthesized compounds. All the drugs were administered orally 30 mins before the carrageenan injection. Acute inflammation was induced in each group by injecting sub-cuteanous 0.1ml of freshly prepared 1% carrageenan (0.1 ml of 1% suspension in 0.9% saline) into the subplantar region of left hind paw The initial reading was taken at 0hr., i.e., immediately after injecting carrageenan and the procedure was repeated at 1, 2, 3, and 4 hours after carrageenan injection with the help of Plethysmometer by water displacement. The mean paw volume at different times was calculated and compared with the control. (Table 2 )
RESULTS AND DISCUSSION
In this study twelve new 3-(4-substituted benzyl)-5-(4-substituted phenyl)-1-phenyl-4, 5-dihydro-1H-pyrazole derivatives (P 25 -P 36 ) were prepared by the action of phenyl hydrazine on 1-(4-substituted phenyl)-4-(4 substituted phenyl) but-3- The compounds were tested in-vitro for their antimicrobial activity. Almost all the compounds have shown some antimicrobial activity. The compound P 25 , P 29 and P 32 showed promising activity against Staphylococcus aureus where as other compounds showed moderate to poor activity. Compound P 25 and P 32 showed significant activity against E. Faecalis and other have shown low activity. Compound P 29 and P 32 have shown significant activity against Escherichia coli and compound P 25 , P 29 and P 31 have shown significant activity against K. pneumonia and rest compounds have shown moderate and low activity. The compound P 31 and P 32 have shown excellent activity against Albican Candida and Aspergillus Niger where as rest of compounds have shown moderate to low activity against these fungi. The synthesized compounds were screened in-vitro for antitubercular activity and compound P 25 , P 29, P 31 and P 32 have exhibited good activity (MIC-3.125 µg/ml) against M. tuberculosis and rest of compounds have have shown moderste to low activity compared with standard Isoniazid (MIC-0.2 µg/ml).
The synthesized compounds were also screened for their in-vivo anti-inflammatory activity. All the compounds have shown varying degree of anti-inflammatory activity by inhibition of rat paw edema volume. Compound P 31 and P 32 have shown good activity as compared with standard Diclofenac sodium and rest of compounds has shown poor activity.
From the study it can be reported that the presence of P-Chloro-phenyl and P-Hydroxyphenyl at position 5 th along with P-Chloro-phenyl/ P-Fluoro-phenyl/ phenyl at position 3 rd of the pyrazoline nucleus have exhibited better all the activities as compared with the other synthesized pyrazoline derivatives. Further optimization of these compounds may result into a more potent and effective agents.
